Considering the importance of autologous SCT in patients with multiple myeloma, we report our successful experience at Tehran Taleghani bone marrow transplantation center using plerixafor to mobilize stem cells in a patient with refractory multiple myeloma who failed mobilization with G-CSF. This evidence concerns the gene CSF3 and plasma cell myeloma.